Autoimmune hemolytic anemia long-term study
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at people with autoimmune hemolytic anemia (AIHA) over time. It aims to understand the disease better and find ways to improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are diagnosed with autoimmune hemolytic anemia (AIHA).
- Your hemoglobin level is below 100 g/L.
- You were treated at the Institute of Hematology and Blood Diseases Hospital in China on or after January 1, 2001.
- You must be available for long-term follow-up.
- You do not have severe health problems or alcohol/drug dependence that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment (Inaticabtagene Autoleucel, a type of CAR-T cell therapy) for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved after at least three prior treatments. The goal is to see if it can help control the disease.
This trial tests a new drug called enatumab for people with warm antibody autoimmune hemolytic anemia (wAIHA) that has come back or not improved after at least two prior treatments. The goal is to see if enatumab can help control the disease.
This trial tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. It aims to see if the therapy can help control the disease and improve anemia symptoms.
This trial looks at how cell therapy may affect your brain function and mood if you have autoimmune hemolytic anemia. It aims to help doctors understand the psychological changes that can happen during treatment.
This study tests whether adding a medication called sirolimus to steroid treatment works better than steroids alone for newly diagnosed autoimmune hemolytic anemia (a condition where your body attacks its own red blood cells). You'll be randomly assigned to one treatment group, and researchers will track how well each approach helps your body recover.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
Hear when a new AIHA - Warm Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.